Compass Therapeutics (NASDAQ:CMPX) Hits New 1-Year High on Analyst Upgrade

Compass Therapeutics, Inc. (NASDAQ:CMPX)’s share price reached a new 52-week high on Monday after Jefferies Financial Group raised their price target on the stock from $7.00 to $8.00. Jefferies Financial Group currently has a buy rating on the stock. Compass Therapeutics traded as high as $3.95 and last traded at $3.94, with a volume of 359782 shares changing hands. The stock had previously closed at $3.50.

CMPX has been the subject of several other reports. Leerink Partners cut Compass Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $5.00 to $4.00 in a research report on Friday, November 15th. Leerink Partnrs downgraded Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th. D. Boral Capital restated a “buy” rating and set a $32.00 target price on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $11.17.

Hedge Funds Weigh In On Compass Therapeutics

Hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC lifted its stake in Compass Therapeutics by 0.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock valued at $4,251,000 after purchasing an additional 19,095 shares during the last quarter. SG Americas Securities LLC raised its position in Compass Therapeutics by 921.6% during the 4th quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock worth $573,000 after purchasing an additional 356,352 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Compass Therapeutics by 2.6% in the fourth quarter. Bank of New York Mellon Corp now owns 237,975 shares of the company’s stock valued at $345,000 after buying an additional 6,041 shares during the period. Barclays PLC raised its holdings in Compass Therapeutics by 195.4% during the 3rd quarter. Barclays PLC now owns 170,245 shares of the company’s stock worth $314,000 after purchasing an additional 112,614 shares during the last quarter. Finally, Rhumbline Advisers raised its stake in Compass Therapeutics by 3.1% during the fourth quarter. Rhumbline Advisers now owns 129,116 shares of the company’s stock worth $187,000 after buying an additional 3,822 shares during the last quarter. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Trading Down 6.4 %

The stock has a market capitalization of $502.20 million, a P/E ratio of -9.86 and a beta of 1.17. The company has a 50-day moving average price of $2.16 and a two-hundred day moving average price of $1.76.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.03. Research analysts forecast that Compass Therapeutics, Inc. will post -0.35 earnings per share for the current year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.